GALXC PLUS Trademark

Trademark Overview

On Monday, January 11, 2021, a trademark application was filed for GALXC PLUS with the United States Patent and Trademark Office. The USPTO has given the GALXC PLUS trademark a serial number of 90458999. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Thursday, September 12, 2024. This trademark is owned by Dicerna Pharmaceuticals, Inc.. The GALXC PLUS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNA interference (RNAi) therapy; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies

Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of disorders outside the liver; research and development of oligonucleotide compounds for targeted gene silencing; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections
galxc plus

General Information

Serial Number90458999
Word MarkGALXC PLUS
Filing DateMonday, January 11, 2021
Status730 - FIRST EXTENSION - GRANTED
Status DateThursday, September 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 16, 2024

Trademark Statements

Goods and ServicesOligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNA interference (RNAi) therapy; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies
Pseudo MarkGALAXY PLUS
Goods and ServicesResearch and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of disorders outside the liver; research and development of oligonucleotide compounds for targeted gene silencing; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, April 10, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSaturday, April 10, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameDicerna Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLexington, MA 02421
Party NameDicerna Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLexington, MA 02421

Trademark Events

Event DateEvent Description
Thursday, January 14, 2021NEW APPLICATION ENTERED
Tuesday, January 19, 2021TEAS VOLUNTARY AMENDMENT RECEIVED
Tuesday, January 19, 2021TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Thursday, February 25, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, February 25, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 25, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Saturday, April 10, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 20, 2021ASSIGNED TO EXAMINER
Tuesday, July 27, 2021NON-FINAL ACTION WRITTEN
Tuesday, July 27, 2021NON-FINAL ACTION E-MAILED
Tuesday, July 27, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, August 12, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 12, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 12, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 31, 2021SUSPENSION LETTER WRITTEN
Tuesday, August 31, 2021LETTER OF SUSPENSION E-MAILED
Tuesday, August 31, 2021NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, January 5, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, January 5, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, January 5, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, January 5, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 5, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, January 13, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, January 13, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, January 13, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, February 2, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, February 2, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 2, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, March 7, 2022REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, May 25, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, May 25, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, May 25, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, September 7, 2022REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Tuesday, February 7, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, February 7, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, February 7, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, April 6, 2023SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Thursday, May 11, 2023NON-FINAL ACTION E-MAILED
Thursday, May 11, 2023NON-FINAL ACTION WRITTEN
Thursday, May 11, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, August 10, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, August 10, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Friday, November 10, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, November 10, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, November 10, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, December 13, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 27, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 16, 2024PUBLISHED FOR OPPOSITION
Tuesday, January 16, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, September 12, 2024SOU TEAS EXTENSION RECEIVED
Thursday, September 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 12, 2024SOU EXTENSION 1 FILED
Thursday, September 12, 2024SOU EXTENSION 1 GRANTED
Tuesday, March 12, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT

Related Keywords

plus galxc delivery diseases oligonucleotide pharmaceutical compounds targeted disorders agents treatment therapies